Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THEMIS: Ticagrelor for Prevention of CV Events in Type 2 Diabetes With Stable Coronary Artery Disease (Japan cohort)
jRCT2080222827Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2015
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM), coronary arteriosclerosis, myocardial infarction (MI) and 1 more comparing Ticagrelor 60 mg twice daily with Placebo twice daily (2 arms). Started Apr 2015; status: completed.
02
Drugs
ticagrelor
03
Conditions
type 2 diabetes mellitus (T2DM)coronary arteriosclerosismyocardial infarction (MI)ischemic stroke
Beyond the preview
Go deeper on jRCT2080222827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222827.